The University of Chicago Header Logo

Connection

Rima McLeod to Humans

This is a "connection" page, showing publications Rima McLeod has written about Humans.
Connection Strength

0.522
  1. Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more. PLoS Negl Trop Dis. 2024 May; 18(5):e0011335.
    View in: PubMed
    Score: 0.031
  2. A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies. Eur J Med Res. 2021 Dec 11; 26(1):143.
    View in: PubMed
    Score: 0.026
  3. Genetic Polymorphisms in Cytokine Genes in Colombian Patients with Ocular Toxoplasmosis. Infect Immun. 2018 04; 86(4).
    View in: PubMed
    Score: 0.020
  4. New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Sci Rep. 2016 07 14; 6:29179.
    View in: PubMed
    Score: 0.018
  5. Understanding Toxoplasmosis in the United States Through "Large Data" Analyses. Clin Infect Dis. 2016 08 15; 63(4):468-75.
    View in: PubMed
    Score: 0.018
  6. Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection Associate With Parasite Genetics. Clin Infect Dis. 2015 Dec 15; 61(12):1831-4.
    View in: PubMed
    Score: 0.017
  7. Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015 Dec 15; 61(12):1815-24.
    View in: PubMed
    Score: 0.017
  8. Utility and limitations of T. gondii-specific IgM serum antibodies in the diagnosis of congenital toxoplasmosis in Porto Alegre. J Pediatr (Rio J). 2014 Jul-Aug; 90(4):329-31.
    View in: PubMed
    Score: 0.015
  9. Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother. 2014; 58(3):1789-92.
    View in: PubMed
    Score: 0.015
  10. Salicylanilide inhibitors of Toxoplasma gondii. J Med Chem. 2012 Oct 11; 55(19):8375-91.
    View in: PubMed
    Score: 0.014
  11. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):14182-7.
    View in: PubMed
    Score: 0.014
  12. Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis. 2012 Jun; 54(11):1595-605.
    View in: PubMed
    Score: 0.013
  13. Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother. 2012 May; 56(5):2666-82.
    View in: PubMed
    Score: 0.013
  14. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 2011 Sep; 5(9):e1333.
    View in: PubMed
    Score: 0.013
  15. Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine. 2011 Jan 17; 29(4):754-62.
    View in: PubMed
    Score: 0.012
  16. Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem. 2010 Sep 09; 53(17):6287-300.
    View in: PubMed
    Score: 0.012
  17. Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine. 2010 May 21; 28(23):3977-89.
    View in: PubMed
    Score: 0.012
  18. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009 Mar; 104(2):320-44.
    View in: PubMed
    Score: 0.011
  19. Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis. 2008 Mar 05; 2(3):e190.
    View in: PubMed
    Score: 0.010
  20. Increased experience and surgical technique lead to improved outcome after ileal pouch-anal anastomosis: a population-based study. Dis Colon Rectum. 2006 Jul; 49(7):958-65.
    View in: PubMed
    Score: 0.009
  21. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006 May 15; 42(10):1383-94.
    View in: PubMed
    Score: 0.009
  22. Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr Infect Dis J. 2006 Mar; 25(3):270-2.
    View in: PubMed
    Score: 0.009
  23. Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother. 2005 Aug; 49(8):3463-7.
    View in: PubMed
    Score: 0.008
  24. Impact of education on knowledge, attitudes, and practices for gestational toxoplasmosis. J Infect Public Health. 2024 Sep; 17(9):102516.
    View in: PubMed
    Score: 0.008
  25. Evaluation of the acceptability of point of care diagnostic test for prenatal toxoplasmosis (translational research phase III). J Infect Public Health. 2023 Jan; 16(1):15-24.
    View in: PubMed
    Score: 0.007
  26. In vitro correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical dependence on parasite strain. J Immunol. 2002 Jul 15; 169(2):966-73.
    View in: PubMed
    Score: 0.007
  27. High performance of a novel point-of-care blood test for Toxoplasma infection in women from diverse regions of Morocco. Emerg Microbes Infect. 2021 Dec; 10(1):1675-1682.
    View in: PubMed
    Score: 0.007
  28. Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. Gastroenterology. 2001 Aug; 121(2):275-81.
    View in: PubMed
    Score: 0.006
  29. Late Diagnosis of Congenital Toxoplasmosis with Macrocephaly in Dizygotic Twins after Incidental Detection of Leukocoria: A Case Report. J Pediatr. 2021 Sep; 236:301-306.
    View in: PubMed
    Score: 0.006
  30. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int J Parasitol. 2001 Feb; 31(2):109-13.
    View in: PubMed
    Score: 0.006
  31. Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice. Sci Rep. 2020 10 12; 10(1):16984.
    View in: PubMed
    Score: 0.006
  32. Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue. J Surg Oncol. 2000 Sep; 75(1):42-50.
    View in: PubMed
    Score: 0.006
  33. The child with congenital toxoplasmosis. Curr Clin Top Infect Dis. 2000; 20:189-208.
    View in: PubMed
    Score: 0.006
  34. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol. 1999 Sep; 29(9):1351-8.
    View in: PubMed
    Score: 0.006
  35. The One Health Approach to Toxoplasmosis: Epidemiology, Control, and Prevention Strategies. Ecohealth. 2019 06; 16(2):378-390.
    View in: PubMed
    Score: 0.005
  36. Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis. Emerg Microbes Infect. 2018 Sep 27; 7(1):165.
    View in: PubMed
    Score: 0.005
  37. Rapid, inexpensive, fingerstick, whole-blood, sensitive, specific, point-of-care test for anti-Toxoplasma antibodies. PLoS Negl Trop Dis. 2018 08; 12(8):e0006536.
    View in: PubMed
    Score: 0.005
  38. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology. 1997 Dec; 113(6):1823-7.
    View in: PubMed
    Score: 0.005
  39. Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries. PLoS Negl Trop Dis. 2017 Jun; 11(6):e0005670.
    View in: PubMed
    Score: 0.005
  40. Prevalence and genetic characterization of Toxoplasma gondii in free-range chickens from grocery stores and farms in Maryland, Ohio and Massachusetts, USA. Parasitol Res. 2017 May; 116(5):1591-1595.
    View in: PubMed
    Score: 0.005
  41. Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis. 1996 Nov; 23(5):1055-60.
    View in: PubMed
    Score: 0.005
  42. Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. Elife. 2016 Jan 29; 5.
    View in: PubMed
    Score: 0.004
  43. Effects of human class I transgenes on Toxoplasma gondii cyst formation. J Immunol. 1994 May 01; 152(9):4537-41.
    View in: PubMed
    Score: 0.004
  44. ALOX12 in human toxoplasmosis. Infect Immun. 2014 Jul; 82(7):2670-9.
    View in: PubMed
    Score: 0.004
  45. Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry. 2013 Dec 23; 52(51):9155-66.
    View in: PubMed
    Score: 0.004
  46. Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. ChemMedChem. 2013 Jul; 8(7):1138-60.
    View in: PubMed
    Score: 0.004
  47. Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii. Infect Immun. 2012 Dec; 80(12):4298-308.
    View in: PubMed
    Score: 0.003
  48. Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J. 2011 Dec; 30(12):1056-61.
    View in: PubMed
    Score: 0.003
  49. Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis. 2011 Dec; 53(11):1081-9.
    View in: PubMed
    Score: 0.003
  50. Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm. 2011 Apr; 19(2):91-102.
    View in: PubMed
    Score: 0.003
  51. Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol. 2011 Apr; 97(2):328-37.
    View in: PubMed
    Score: 0.003
  52. Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des. 2011 May; 25(5):403-11.
    View in: PubMed
    Score: 0.003
  53. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun. 2011 Feb; 79(2):756-66.
    View in: PubMed
    Score: 0.003
  54. Immunogenetics of Toxoplasma gondii informs vaccine design. Trends Parasitol. 2010 Nov; 26(11):550-5.
    View in: PubMed
    Score: 0.003
  55. P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol. 2010 Jun 15; 184(12):7040-6.
    View in: PubMed
    Score: 0.003
  56. Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz. 2009 Mar; 104(2):162-9.
    View in: PubMed
    Score: 0.003
  57. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol. 2008 Aug; 126(8):1152-6.
    View in: PubMed
    Score: 0.003
  58. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol. 2008 Sep; 146(3):375-384.
    View in: PubMed
    Score: 0.003
  59. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One. 2008 Jun 04; 3(6):e2285.
    View in: PubMed
    Score: 0.003
  60. Cataracts in congenital toxoplasmosis. J AAPOS. 2007 Dec; 11(6):551-4.
    View in: PubMed
    Score: 0.002
  61. Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids. Biochemistry. 2007 Dec 04; 46(48):13882-90.
    View in: PubMed
    Score: 0.002
  62. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology. 2008 Mar; 115(3):553-559.e8.
    View in: PubMed
    Score: 0.002
  63. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006 Aug; 118(2):e379-90.
    View in: PubMed
    Score: 0.002
  64. The unusual mitochondrial compartment of Cryptosporidium parvum. Trends Parasitol. 2005 Feb; 21(2):68-74.
    View in: PubMed
    Score: 0.002
  65. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol. 2005 Feb; 192(2):564-71.
    View in: PubMed
    Score: 0.002
  66. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol. 2003 Jun; 135(6):779-84.
    View in: PubMed
    Score: 0.002
  67. Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol. 2002 May; 18(5):198-201.
    View in: PubMed
    Score: 0.002
  68. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet. 2001 Oct; 29(2):223-8.
    View in: PubMed
    Score: 0.002
  69. Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc Natl Acad Sci U S A. 1999 Nov 09; 96(23):13387-92.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.